Trial · NCT00837200
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
NCT00837200, Phase 2, Terminated, Milton S. Hershey Medical Center; results first posted 2014-08-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies. Trials, record NCT00837200. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00837200
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
- NCT number
- NCT00837200
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 13 participants, actual
- Lead sponsor
- Milton S. Hershey Medical Center
- Conditions
- Non-hodgkins Lymphoma, Hodgkins Lymphoma, Multiple Myeloma
- Interventions
- Oncaspar, Doxil, Decadron
- First posted
- 2009-02-05
- Last updated
- 2017-07-24
- Results first posted
- 2014-08-20
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tumor Response | 16 weeks | * Leukemias mainly w/peripheral blood counts/diff every 2 wks/CLL, CT scan before initiation of study, 2nd CT after EOT, no CT at FU * Lymphomas restaged w/CT scans of chest/abdomen/pelvis or PET/CT scans after 2 cycles * MM monitored w/tumor markers monthly Quantitative immunoglobulins/SPEP w/quantitative M component in MM pts producing full antibody, UPEP w/ quantitative Bence-Jones in MM pts producing only light chains/Serum free light chains obtained all pts/Skeletal surveys at baseline Tumor responses:CR complete resolution of all detectable clinical/radiographic evidence of disease, disappearance of all disease related symptoms, and normalization of biochemical abnormalities for at least 6 wks following treatment and no BM infiltration;PR reduction of all measurable lesions by 50% or more/no new lesions;SD not fulfilling PR criteria/no evidence disease progression;PD increase original tumor mass by more than 25% lesion/new lesion * Stable disease \> 2mo was a response |
| Primary | Study Specific Measure (Response) | 16 Weeks | |
| Primary | Study Specific Measure (Number of Participants Taken Off Study) | 16 weeks |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Tumor Response | 16 weeks | participants | NUMBER | |
| PRIMARY | Study Specific Measure (Response) | 16 Weeks | participants | NUMBER | |
| PRIMARY | Study Specific Measure (Number of Participants Taken Off Study) | 16 weeks | participants | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Tumor Response | ODD Regimen | 2 | participants | ||
| Study Specific Measure (Response) | ODD Regimen | Not Evaluable for Response | 1 | participants | |
| Study Specific Measure (Response) | ODD Regimen | Stable Disease > 2 months | 2 | participants | |
| Study Specific Measure (Response) | ODD Regimen | Progressive Disease | 10 | participants | |
| Study Specific Measure (Number of Participants Taken Off Study) | ODD Regimen | Due to Oncaspar-Related Toxicities | 1 | participants | |
| Study Specific Measure (Number of Participants Taken Off Study) | ODD Regimen | Not De to Oncaspar-Related Toxicities | 12 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | ODD Regimen | 13 | |
| Overall Study | COMPLETED | ODD Regimen | 13 | |
| Overall Study | NOT COMPLETED | ODD Regimen | 0 |
Source ClinicalTrials.gov
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Decreased WBC | Blood and lymphatic system disorders | ODD Regimen | 7 | 13 | |
| other | Decreased ANC | Blood and lymphatic system disorders | ODD Regimen | 4 | 13 | |
| other | Elevated AST | Metabolism and nutrition disorders | ODD Regimen | 3 | 13 | |
| other | Elevated ALT | Metabolism and nutrition disorders | ODD Regimen | 3 | 13 | |
| other | Decreased Platelets | Blood and lymphatic system disorders | ODD Regimen | 6 | 13 | |
| other | Decreased Hemoglobin | Blood and lymphatic system disorders | ODD Regimen | 8 | 13 | |
| serious | Pneumonia | Respiratory, thoracic and mediastinal disorders | ODD Regimen | 1 | 13 | 1 |
| serious | Acute Renal Failure | Renal and urinary disorders | ODD Regimen | 1 | 13 | 1 |
| serious | Mucositis | Gastrointestinal disorders | ODD Regimen | 1 | 13 | |
| serious | Elevated Alk Phos | Metabolism and nutrition disorders | ODD Regimen | 1 | 13 |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ODD Regimen | ||
| Total, other adverse events | ODD Regimen | 13 | 13 |
| Total, serious adverse events | ODD Regimen | 9 | 13 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00837200
GET https://conductscience.org/api/trials/v1/NCT00837200/registered